SBFMW (Sunshine Biopharma) PB Ratio: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SBFMW Sunshine Biopharma Inc SBFMW
34 GF Score
Price $0.09
! 4 Warning Signs
View Full Analysis

What is Sunshine Biopharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-09), Sunshine Biopharma's share price is $0.0851. Sunshine Biopharma's Book Value per Share for the quarter that ended in Jun. 2026 was $0.00. Hence, Sunshine Biopharma's PB Ratio of today is .

The historical rank and industry rank for Sunshine Biopharma's PB Ratio or its related term are showing as below:

SBFMW' s PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.26   Max: 1.05
Current: 0.1

During the past 13 years, Sunshine Biopharma's highest PB Ratio was 1.05. The lowest was 0.01. And the median was 0.26.

SBFMW's PB Ratio is ranked better than
99.56% of 918 companies
in the Drug Manufacturers industry
Industry Median: 1.98 vs SBFMW: 0.10

During the past 12 months, Sunshine Biopharma's average Book Value Per Share Growth Rate was -79.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -87.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sunshine Biopharma was -87.10% per year. The lowest was -87.10% per year. And the median was -87.10% per year.

Back to Basics: PB Ratio


Sunshine Biopharma  (NAS:SBFMW) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sunshine Biopharma PB Ratio Related Terms


Sunshine Biopharma PB Ratio Historical Data

* Premium members only.

The historical data trend for Sunshine Biopharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma PB Ratio Chart

Sunshine Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sunshine Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SBFMW vs BUDZ, CVSI, LVRLF: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's PB Ratio falls into.


SBFMW
34GF Score
Sunshine Biopharma Inc SBFMW
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Biopharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sunshine Biopharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=0.0851/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Sunshine Biopharma Business Description

Other Exchanges SBFM:USA
Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score

Get the complete analysis for SBFMW

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price